Treating Heart Failure With hPSC-CMs

General Information

Summary Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in a human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes. Cellular replacement therapy is a potential approach to repair damaged myocardial tissue, restore cardiac function, which has become a new strategy for the treatment of heart failure. The purpose of this study is to assess the safety, feasibility and efficacy of intramyocardial delivery of regenerated cardiomyocytes at the time of coronary artery bypass grafting in patients with chronic ischemic cardiomyopathy.
Description Patients with heart failure will be treated with allogenic human induced pluripotent stem cell-derived cardiomyocytes ( hPSC-CM ) from healthy donors. The cells will be injected directly into the myocardium at time of coronary artery bypass grafting. Patients will be followed for 12 months for safety, feasibility and efficacy assessment of therapy.
Clinical trials phase Not applicable
Start date (estimated) 2018-12-01
End date (estimated) 2020-12-01
Clinical feature
Label Ischemic Heart Disease
Description A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries, to obstruction by a thrombus, or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).

Administrative Information

NCT Number NCT03763136
Source weblink
Regulatory body approval
Public contact
Sponsors Help Therapeutics

Cell Line


Recruitment Status Recruiting
Estimated number of participants 15